These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33170091)

  • 1. Drug repurposing for Alzheimer's disease:
    Kumar N; Gahlawat A; Kumar RN; Singh YP; Modi G; Garg P
    J Biomol Struct Dyn; 2022 Apr; 40(7):2878-2892. PubMed ID: 33170091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential alternatives to current cholinesterase inhibitors: an
    Kundu D; Dubey VK
    Drug Dev Ind Pharm; 2021 Jun; 47(6):919-930. PubMed ID: 34219594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study.
    Mateev E; Kondeva-Burdina M; Georgieva M; Zlatkov A
    J Mol Graph Model; 2023 Jul; 122():108471. PubMed ID: 37087882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer's Disease.
    Iman K; Mirza MU; Mazhar N; Vanmeert M; Irshad I; Kamal MA
    CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):54-68. PubMed ID: 29336270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacophore mapping-based virtual screening followed by molecular docking studies in search of potential acetylcholinesterase inhibitors as anti-Alzheimer's agents.
    Ambure P; Kar S; Roy K
    Biosystems; 2014 Feb; 116():10-20. PubMed ID: 24325852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
    Kumar S; Chowdhury S; Kumar S
    BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
    Son M; Park C; Rampogu S; Zeb A; Lee KW
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
    Hu XM; Dong W; Cui ZW; Gao CZ; Yu ZJ; Yuan Q; Min ZL
    J Mol Model; 2018 Jun; 24(7):151. PubMed ID: 29869722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The exploration of novel Alzheimer's therapeutic agents from the pool of FDA approved medicines using drug repositioning, enzyme inhibition and kinetic mechanism approaches.
    Hassan M; Raza H; Abbasi MA; Moustafa AA; Seo SY
    Biomed Pharmacother; 2019 Jan; 109():2513-2526. PubMed ID: 30551512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lead Identification Through
    Agarwal D; Kumar S; Ambatwar R; Bhanwala N; Chandrakar L; Khatik GL
    Cent Nerv Syst Agents Med Chem; 2024; 24(2):219-242. PubMed ID: 38288823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals.
    Amat-Ur-Rasool H; Ahmed M
    PLoS One; 2015; 10(9):e0136509. PubMed ID: 26325402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease.
    Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J
    ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An
    Potshangbam AM; Nandeibam A; Amom T; Potshangbam N; Rahaman H; Rathore RS; Singh LR; Khan A
    J Biomol Struct Dyn; 2022 Mar; 40(4):1521-1533. PubMed ID: 33021148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in silico investigation of FDA-approved drugs to be repurposed against Alzheimer's disease.
    Akkaya D; Seyhan G; Sari S; Barut B
    Drug Dev Res; 2024 May; 85(3):e22184. PubMed ID: 38634273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potential inhibitor against human acetylcholinesterase: a molecular docking and molecular dynamics investigation.
    Singh SP; Gupta D
    Comput Biol Chem; 2017 Jun; 68():224-230. PubMed ID: 28432980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's.
    Dhanjal JK; Sharma S; Grover A; Das A
    Biomed Pharmacother; 2015 Apr; 71():146-52. PubMed ID: 25960230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico and in vitro anti-AChE activity investigations of constituents from Mytragyna speciosa for Alzheimer's disease treatment.
    Innok W; Hiranrat A; Chana N; Rungrotmongkol T; Kongsune P
    J Comput Aided Mol Des; 2021 Mar; 35(3):325-336. PubMed ID: 33439402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
    Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2D-QSAR, molecular docking and MD simulation based virtual screening of the herbal molecules against Alzheimer's disorder: an approach to predict CNS activity.
    Thakur A; Sharma B; Parashar A; Sharma V; Kumar A; Mehta V
    J Biomol Struct Dyn; 2024; 42(1):148-162. PubMed ID: 36970779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.